Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers

The amyloid β peptide (Aβ) is a key player in the etiology of Alzheimer disease (AD), yet a systematic investigation of its molecular interactions has not been reported. Here we identified by quantitative mass spectrometry proteins in human brain extract that bind to oligomeric Aβ1-42 (oAβ1-42) and/or monomeric Aβ1-42 (mAβ1-42) baits. Remarkably, the cyclic neuroendocrine peptide somatostatin-14 (SST14) was observed to be the most selectively enriched oAβ1-42 binder. The binding interface comprises a central tryptophan within SST14 and the N-terminus of Aβ1-42. The presence of SST14 inhibited Aβ aggregation and masked the ability of several antibodies to detect Aβ. Notably, Aβ1-42, but not Aβ1-40, formed in the presence of SST14 oligomeric assemblies of 50 to 60 kDa that were visualized by gel electrophoresis, nanoparticle tracking analysis and electron microscopy. These findings may be relevant for Aβ-directed diagnostics and may signify a role of SST14 in the etiology of AD. DOI: http://dx.doi.org/10.7554/eLife.28401.001

[1]  Shaomin Li,et al.  Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate , 2017, The Journal of Neuroscience.

[2]  E. Wanker,et al.  Amyloid-β(1–42) Aggregation Initiates Its Cellular Uptake and Cytotoxicity * , 2016, The Journal of Biological Chemistry.

[3]  G. Schmitt-Ulms,et al.  The Human Tau Interactome: Binding to the Ribonucleoproteome, and Impaired Binding of the Proline-to-Leucine Mutant at Position 301 (P301L) to Chaperones and the Proteasome* , 2015, Molecular & Cellular Proteomics.

[4]  G. Schmitt-Ulms,et al.  CRISPR-Cas9-Based Knockout of the Prion Protein and Its Effect on the Proteome , 2014, PloS one.

[5]  Kevin H. Chen,et al.  A Fibril-Like Assembly of Oligomers of a Peptide Derived from β-Amyloid , 2014, Journal of the American Chemical Society.

[6]  Saikat Ghosh,et al.  Elucidating the Role of Disulfide Bond on Amyloid Formation and Fibril Reversibility of Somatostatin-14 , 2014, The Journal of Biological Chemistry.

[7]  M. Rowan,et al.  mGlu5 receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivo , 2014, Nature Communications.

[8]  Andrew R. Jones,et al.  ProteomeXchange provides globally co-ordinated proteomics data submission and dissemination , 2014, Nature Biotechnology.

[9]  S. Yan,et al.  Identification of human ABAD inhibitors for rescuing Aβ-mediated mitochondrial dysfunction. , 2014, Current Alzheimer research.

[10]  A. Vortmeyer,et al.  Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein , 2013, Neuron.

[11]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[12]  David A Bennett,et al.  Brain amyloid-β oligomers in ageing and Alzheimer's disease. , 2013, Brain : a journal of neurology.

[13]  C. Cotman,et al.  β-Amyloid (Aβ) Oligomers Impair Brain-derived Neurotrophic Factor Retrograde Trafficking by Down-regulating Ubiquitin C-terminal Hydrolase, UCH-L1* , 2013, The Journal of Biological Chemistry.

[14]  Winnie S. Liang,et al.  Reduced RAN Expression and Disrupted Transport between Cytoplasm and Nucleus; A Key Event in Alzheimer’s Disease Pathophysiology , 2013, PloS one.

[15]  Johannes Griss,et al.  The Proteomics Identifications (PRIDE) database and associated tools: status in 2013 , 2012, Nucleic Acids Res..

[16]  Lukas N. Mueller,et al.  Interactome of the amyloid precursor protein APP in brain reveals a protein network involved in synaptic vesicle turnover and a close association with Synaptotagmin-1. , 2012, Journal of proteome research.

[17]  L. Mucke,et al.  Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.

[18]  T. Exner,et al.  Interaction structure of the complex between neuroprotective factor humanin and Alzheimer's β‐amyloid peptide revealed by affinity mass spectrometry and molecular modeling , 2012, Journal of peptide science : an official publication of the European Peptide Society.

[19]  J. Jhamandas,et al.  Amyloid β (Aβ) Peptide Directly Activates Amylin-3 Receptor Subtype by Triggering Multiple Intracellular Signaling Pathways* , 2012, The Journal of Biological Chemistry.

[20]  S. Marini,et al.  Somatostatin Modulates Insulin-Degrading-Enzyme Metabolism: Implications for the Regulation of Microglia Activity in AD , 2012, PloS one.

[21]  S. Lesné,et al.  Soluble Aβ oligomer production and toxicity , 2012, Journal of neurochemistry.

[22]  David Klenerman,et al.  The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β1−40 peptide , 2011, Nature Structural &Molecular Biology.

[23]  D. Eisenberg,et al.  Characteristics of amyloid-related oligomers revealed by crystal structures of macrocyclic β-sheet mimics. , 2011, Journal of the American Chemical Society.

[24]  D. Selkoe,et al.  Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.

[25]  L. Lue,et al.  Inhibition of Amyloid-β (Aβ) Peptide-Binding Alcohol Dehydrogenase-Aβ Interaction Reduces Aβ Accumulation and Improves Mitochondrial Function in a Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[26]  A. Chakrabartty,et al.  Cell Surface Binding and Internalization of Aβ Modulated by Degree of Aggregation , 2011, International journal of Alzheimer's disease.

[27]  W. Klein,et al.  ADDLs and the signaling web that leads to Alzheimer’s disease , 2010, Neuropharmacology.

[28]  W. Surewicz,et al.  Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. , 2010, The Journal of biological chemistry.

[29]  Judianne Davis,et al.  Structural conversion of neurotoxic amyloid-β(1–42) oligomers to fibrils , 2010, Nature Structural &Molecular Biology.

[30]  Vasco Filipe,et al.  Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates , 2010, Pharmaceutical Research.

[31]  Sara Linse,et al.  Amyloid β-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. , 2010, ACS chemical neuroscience.

[32]  J. Jia,et al.  Association between somatostatin gene polymorphisms and sporadic Alzheimer's disease in Chinese population , 2009, Neuroscience Letters.

[33]  D. Hoyer,et al.  Somatostatin, Alzheimer's disease and cognition: An old story coming of age? , 2009, Progress in Neurobiology.

[34]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[35]  A. Anel,et al.  Amyloid-precursor protein mediates neuronal toxicity of amyloid through Go protein activation , 2009 .

[36]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[37]  David Eisenberg,et al.  In Brief , 2009, Nature Reviews Neuroscience.

[38]  G. Zamponi Faculty Opinions recommendation of Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. , 2009 .

[39]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[40]  W. Klein,et al.  Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers , 2009, Proceedings of the National Academy of Sciences.

[41]  S. Pizzo,et al.  Amyloid precursor protein and amyloid β-peptide bind to ATP synthase and regulate its activity at the surface of neural cells , 2008, Molecular Psychiatry.

[42]  B. Penke,et al.  Characterization of the interaction between Aβ 1–42 and glyceraldehyde phosphodehydrogenase , 2008, Journal of peptide science : an official publication of the European Peptide Society.

[43]  A. Hernández-Pinto,et al.  Somatostatin and Alzheimer's disease , 2008, Molecular and Cellular Endocrinology.

[44]  O. Arancio,et al.  Receptor for Advanced Glycation End Product-Dependent Activation of p38 Mitogen-Activated Protein Kinase Contributes to Amyloid-β-Mediated Cortical Synaptic Dysfunction , 2008, The Journal of Neuroscience.

[45]  A. Draguhn,et al.  Amyloid β Oligomers (Aβ1–42 Globulomer) Suppress Spontaneous Synaptic Activity by Inhibition of P/Q-Type Calcium Currents , 2008, The Journal of Neuroscience.

[46]  P. S. St George-Hyslop,et al.  The in Vivo Brain Interactome of the Amyloid Precursor Protein*S , 2008, Molecular & Cellular Proteomics.

[47]  H. Soininen,et al.  Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients , 2007, Journal of Neurology.

[48]  William Stafford Noble,et al.  Semi-supervised learning for peptide identification from shotgun proteomics datasets , 2007, Nature Methods.

[49]  C. Valéry,et al.  Spontaneous fibrillation of the native neuropeptide hormone Somatostatin-14. , 2007, Journal of structural biology.

[50]  J. Nowick,et al.  An Artificial β-Sheet That Dimerizes through Parallel β-Sheet Interactions , 2007 .

[51]  R. Rydel,et al.  α2β1 and αVβ1 integrin signaling pathways mediate amyloid-β-induced neurotoxicity , 2007, Neurobiology of Aging.

[52]  O. Vitolo,et al.  Ubiquitin Hydrolase Uch-L1 Rescues β-Amyloid-Induced Decreases in Synaptic Function and Contextual Memory , 2006, Cell.

[53]  D. Bredesen,et al.  Aβ induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597–624) , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[55]  B. Strooper,et al.  Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin , 2005, Nature Cell Biology.

[56]  P. Keller,et al.  Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .

[57]  K. Medzihradszky,et al.  Identification of synaptic plasma membrane proteins co‐precipitated with fibrillar β‐amyloid peptide , 2005, Journal of neurochemistry.

[58]  I. Kohane,et al.  Gene regulation and DNA damage in the ageing human brain , 2004, Nature.

[59]  Xi Chen,et al.  Materials and Methods Som Text Figs. S1 and S2 Table S1 References Abad Directly Links A␤ to Mitochondrial Toxicity in Alzheimer's Disease , 2022 .

[60]  Allan I. Levey,et al.  Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases* , 2004, Journal of Biological Chemistry.

[61]  G. Sobue,et al.  A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  D. Selkoe Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[63]  Xi Chen,et al.  An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease , 1997, Nature.

[64]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[65]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[66]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[67]  T. Wisniewski,et al.  The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. , 1993, The Biochemical journal.

[68]  K. Davis,et al.  Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex , 1993, Neuroscience Letters.

[69]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[70]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[71]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[72]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[73]  H. Wiśniewski,et al.  Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. , 1986, The Journal of biological chemistry.

[74]  M. Beal,et al.  Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. , 1985, Science.

[75]  T. Crow,et al.  Location of neuronal tangles in somatostatin neurones in Alzheimer's disease , 1985, Nature.

[76]  F. Bloom,et al.  Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients , 1985, Nature.

[77]  R. Katzman.,et al.  Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa , 1980, Nature.

[78]  D. Veber,et al.  Highly active cyclic and bicyclic somatostatin analogues of reduced ring size , 1979, Nature.

[79]  N. Ling,et al.  Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone , 1973, Science.

[80]  D. Bennett,et al.  Brain amyloid- b oligomers in ageing and Alzheimer’s disease , 2013 .

[81]  G. Schmitt-Ulms,et al.  Time-controlled transcardiac perfusion crosslinking for in vivo interactome studies. , 2012, Methods in molecular biology.

[82]  J. Ávila,et al.  Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients. , 2010, Journal of Alzheimer's disease : JAD.

[83]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[84]  J. Nowick,et al.  An artificial beta-sheet that dimerizes through parallel beta-sheet interactions. , 2007, Journal of the American Chemical Society.

[85]  R. Rydel,et al.  Alpha2beta1 and alphaVbeta1 integrin signaling pathways mediate amyloid-beta-induced neurotoxicity. , 2007, Neurobiology of aging.

[86]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[87]  Nobuhisa Iwata,et al.  Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. , 2005, Nature medicine.

[88]  P. Keller,et al.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. , 2005, Journal of neurochemistry.

[89]  W. Markesbery,et al.  Quantitative Proteomic Analysis of Mitochondria from Primary Neuron Cultures Treated with Amyloid Beta Peptide , 2004, Neurochemical Research.

[90]  B. Sommer,et al.  Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. , 2000, Nature neuroscience.

[91]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.